Combinature appoints Harald Labischinski as Chief Executive Officer
Combinature Biopharm AG announced that the company's Supervisory Board has appointed Prof. Dr. Harald Labischinski as a member of the Management Board and Chief Executive Officer, with effect as of 15 April 2005.
Harald Labischinski is an internationally recognised expert in the development of antibiotics, who worked for Bayer Health Care AG for the past 12 years, including several years as head of anti-infectives and antibiotics research. In addition, he was responsible for early and late stage portfolio management in the anti-infectives business area including in- and out-licensing activities and external collaborations. Before that, Harald Labischinski spent more than 10 years in a managerial position at the Robert Koch Institute for Infection Research in Berlin. He also has excellent connections to the world of academic research, for example as the current president of the German Association for General and Applied Microbiology (VAAM). Dr. Rolf Zettl, co-founder of the company and CEO since November 2000, will remain on the company's Management Board as Chief Business Officer.
Most read news
Organizations
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Milestone for the analysis of human proteomes - Synthetic peptides and spectra for proteomics
Novel 'antisense' therapies protect primates from lethal Ebola and Marburg viruses
Apitope and Merck Serono Announce Licensing Agreement on Novel Peptide Therapeutics for the Treatment of Multiple Sclerosis
FDA Approves First Drug for Huntington's Disease
List_of_Corydoras_species

Dynavax Technologies - Berkeley, USA
Cri_du_chat
Intercell's Japanese Encephalitis vaccine safe in Phase III trials
